A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors

Exclusion Criteria

• •A history of or current conditions and diseases affecting the digestive tract, such as indeterminate colitis, suspicion of ischemic colitis, radiation colitis, or microscopic colitis, Crohn's disease, fistulas or abdominal abscesses, colonic mucosal dysplasia, intestinal obstruction, toxic megacolon, or unremoved adenomatous colonic polyps
• •Prior or planned surgery for UC
• •Past or present ileostomy or colostomy
• •Any prior treatment with etrolizumab or other anti-integrin agents (including natalizumab, vedolizumab, and efalizumab)
• •Any prior treatment with anti-adhesion molecules (e.g. anti-MAdCAM-1)
• •Any prior treatment with rituximab
• •Any treatment with tofacitinib during screening
• •Congenital or acquired immune deficiency, chronic hepatitis B or C infection, human immunodeficiency virus (HIV) positive, or history of tuberculosis (active or latent)
• •Evidence of or treatment for Clostridium difficile or clinically significant cytomegalovirus (CMV) colitis within 60 days prior to Day 1
• •Evidence of or treatment for other intestinal pathogens within 30 days prior to Day 1
• •History of recurrent opportunistic infections and/or severe disseminated viral infections
• •History of organ transplant
• •Any major episode of infection requiring treatment with intravenous (IV) antibiotics within 8 weeks prior to screening or oral antibiotics within 4 weeks prior to screening
• •Received a live attenuated vaccine within 4 weeks prior to Day 1